Kynexis Announces Results for KYN-5356 in Cognitive Impairment
17 Dec 2024 //
GLOBENEWSWIRE
Kynexis Appoints SAB For Brain Disease Precision Therapeutics
29 May 2024 //
GLOBENEWSWIRE
Kynexis Announces Initiation of First-in-Human Phase 1 Study of KYN-5356
04 Jan 2024 //
GLOBENEWSWIRE